Put Antipsychotics for Agitation in Dementia in Perspective

September 2023

A new indication for brexpiprazole (Rexulti) will raise questions about treating agitation in dementia with antipsychotics.

Brexpiprazole is a second-generation antipsychotic already approved for schizophrenia and as an add-on for depression.

Now you’ll hear that brexpiprazole is the first med FDA-approved for agitation in patients with Alzheimer’s dementia.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote